Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Lichtenstein

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|April 24, 2013
Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumabShaun Ittiara, Michael P Blair, Michael J Shapiro, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 18, 2012
Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurityRavi D Patel, Michael P Blair, Michael J Shapiro, et al.
Advances in Therapy|November 22, 2007
Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studiesSteven J Lichtenstein, Rudolph S Wagner, Tiffany Jamison, et al.
Ophthalmology|March 8, 2003
A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitisIvan R Schwab, Mitchell Friedlaender, James McCulley, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 12, 2012
Reactivation of retinopathy of prematurity after bevacizumab injectionJennifer Hu, Michael P Blair, Michael J Shapiro, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 7, 2007
Safety and tolerability of olopatadine 0.2% in children and adolescentsSteven J Lichtenstein, Terry A Pasquine, Michael R Edwards, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 20, 2010
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicinRudolph S Wagner, David B Granet, Steven J Lichtenstein, et al.
Journal of Pediatric Ophthalmology and Strabismus|November 15, 2011
Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throatSteven J Lichtenstein, Liberation De Leon, Warren Heller, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|May 11, 2011
Peripheral retinal nonperfusion in septo-optic dysplasia (de Morsier syndrome)Daniel F Kiernan, Omar Al-Heeti, Michael P Blair, et al.
Advances in Therapy|January 1, 2008
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisStephen V Scoper, Gregg J Berdy, Steven J Lichtenstein, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|April 24, 2013
Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumabShaun Ittiara, Michael P Blair, Michael J Shapiro, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 18, 2012
Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurityRavi D Patel, Michael P Blair, Michael J Shapiro, et al.
Advances in Therapy|November 22, 2007
Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studiesSteven J Lichtenstein, Rudolph S Wagner, Tiffany Jamison, et al.
Ophthalmology|March 8, 2003
A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitisIvan R Schwab, Mitchell Friedlaender, James McCulley, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 12, 2012
Reactivation of retinopathy of prematurity after bevacizumab injectionJennifer Hu, Michael P Blair, Michael J Shapiro, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 7, 2007
Safety and tolerability of olopatadine 0.2% in children and adolescentsSteven J Lichtenstein, Terry A Pasquine, Michael R Edwards, et al.
Clinical Ophthalmology (Auckland, N.Z.)|February 20, 2010
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicinRudolph S Wagner, David B Granet, Steven J Lichtenstein, et al.
Journal of Pediatric Ophthalmology and Strabismus|November 15, 2011
Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throatSteven J Lichtenstein, Liberation De Leon, Warren Heller, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|May 11, 2011
Peripheral retinal nonperfusion in septo-optic dysplasia (de Morsier syndrome)Daniel F Kiernan, Omar Al-Heeti, Michael P Blair, et al.
Advances in Therapy|January 1, 2008
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisStephen V Scoper, Gregg J Berdy, Steven J Lichtenstein, et al.
Pageof 2